ATR and breast carcinoma: In addition, Bukhari et al. recently reported that a combination of bioavailable AZD1775 and ATR inhibitor AZD6738 strongly suppressed metastasis with minimal side effects in an orthotopic breast cancer model (Bukhari et al., 2019).